apixaban / Generic mfg. - LARVOL DELTA

Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study. (PubMed, J Cardiovasc Pharmacol Ther) - "Adherence levels for dabigatran, rivaroxaban, apixaban, and edoxaban were compared at 3, 6, 9, and 12 months. The NVBP policy improves adherence short-term, but long-term effects are limited. Targeted interventions are necessary for high-risk populations."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders

Interval Appearance of Hematoidin Crystals in Empyema. (PubMed, QJM) - "A 63-year-old man receiving apixaban for pulmonary embolism developed a loculated empyema requiring repeated pleural drainage...Hematoidin is an iron-free pigment produced during hemoglobin degradation following erythrocyte extravasation, particularly in closed spaces with low oxygen tension. The interval appearance of these crystals was consistent with antecedent bleeding into the pleural space and illustrates how prior bleeding may leave a recognizable microscopic footprint during the evolution of an infected pleural collection."

Journal • Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Full versus abbreviated lead-in durations of apixaban and rivaroxaban after initial parenteral anticoagulation in the treatment of venous thromboembolism. (PubMed, Thromb Res) - No abstract available

Journal • Cardiovascular • Venous Thromboembolism

From Injections to Implementation: Standardizing Extended Oral Thromboprophylaxis After Bariatric Surgery. (PubMed, Am Surg) - "One patient (0.15%) had a bleeding complication requiring reoperation for an intramural hematoma causing small bowel obstruction.ConclusionsA standardized institutional protocol utilizing apixaban 2.5 mg twice daily for 30 days following bariatric surgery can be implemented with high adherence and low complication rates. Further prospective, multi-institutional studies are warranted to validate these findings and refine patient selection."

Journal • Cardiovascular • Gastrointestinal Disorder • Venous Thromboembolism

Severe Supratherapeutic international normalized ratio (INR) following concomitant Ribociclib and warfarin therapy. (PubMed, J Oncol Pharm Pract) - "She had been transitioned from apixaban to warfarin approximately 2 months earlier due to concern for a potential interaction between apixaban and ribociclib. Although warfarin allows monitoring via INR, insufficient early monitoring may increase patient risk. Weekly INR monitoring during the first 2 cycles of ribociclib may improve safety."

Journal • Atrial Fibrillation • Cardiovascular

ProApix: Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma (clinicaltrials.gov) - P=N/A | N=36 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Trial completion date: Sep 2027 ➔ Mar 2028 | Trial primary completion date: Mar 2027 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics

Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. (PubMed, J Clin Pharmacol) - "The predicted small reductions in apixaban and rivaroxaban exposures (AUCinf <10%) are not expected to be clinically relevant since a 20% no-effect boundary is typically used to determine the clinical impact of a DDI. The PBPK model predictions are consistent with the apixaban and rivaroxaban labels, which do not warn against co-administration with weak or moderate CYP3A inducers, such as suzetrigine."

Journal • Pain

Ischemic Stroke After Anticoagulation Discontinuation Following Apparent Resolution of Left Ventricular Thrombus: A Case Report. (PubMed, Cureus) - "He was treated with apixaban and guideline-directed medical therapy...This case highlights the diagnostic uncertainty that may remain after apparent resolution of LVT on echocardiography and emphasizes the need for careful clinical judgment before stopping anticoagulation in patients with severe left ventricular dysfunction and high embolic risk. Advanced imaging, such as cardiac magnetic resonance imaging or contrast-enhanced echocardiography, may be considered when diagnostic certainty is required."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Heart Failure • Hypertension • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Thrombosis

The COBRA Trial- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism, incl. discussion and Q&A (ERS 2026) - No abstract available

Cardiovascular • Venous Thromboembolism

On-Premise Detection of a Guideline-Driven Oral Anticoagulation Shift in German Doctors' Letters Using Local Large Language Models. (PubMed, Stud Health Technol Inform) - "We show that under strict clinical constraints, local LLM-based MIE models trained on CARDIO:DE can support medication trend analysis in unseen older German doctors' letters and provide an on-premise method for downstream clinical text analysis."

Journal • Atrial Fibrillation • Cardiovascular

SPONTANEOUS HEMORRHAGIC TAMPONADE ON APIXABAN IN SEVERE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION WITH JAK2-POSITIVE MYELOPROLIFERATIVE NEOPLASM (CHEST 2026) - No abstract available

Cardiovascular • Hematological Disorders • Myeloproliferative Neoplasm • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • JAK2

APIXABAN: PRECIPITATED PULMONARY FIBROSIS IN AN OLDER PATIENT - A CASE REPORT (CHEST 2026) - No abstract available

Case report • Clinical • Immunology • Pulmonary Disease • Respiratory Diseases

EXTENSIVE CUTANEOUS NECROSIS ASSOCIATED WITH APIXABAN: A CASE REPORT OF A RARE ADVERSE DRUG REACTION (CHEST 2026) - No abstract available

Adverse drug reaction • Case report • Clinical • Critical care • Hematological Disorders • Oncology

OPTIMAL TIMING FOR APIXABAN RESUMPTION FOLLOWING HEMATEMESIS IN ATRIAL FIBRILLATION (CHEST 2026) - No abstract available

Atrial Fibrillation • Cardiovascular

A RARE COMPLICATION OF ATRIAL FLUTTER WITH RVR: ISOLATED RIGHT VENTRICULAR THROMBUS TREATED WITH APIXABAN (CHEST 2026) - No abstract available

Cardiovascular • Thrombosis

Real-World Assessment of Direct Oral Factor Xa Inhibitors: Dosing Appropriateness, Drug Exposure, and Inter-Platform Comparability of Chromogenic Anti-Xa Assays. (PubMed, Diagnostics (Basel)) - " This single-center retrospective study included 392 plasma samples from 292 patients with atrial fibrillation treated with apixaban (n = 207), edoxaban (n = 147), or rivaroxaban (n = 38). Chromogenic anti-factor Xa assays showed strong inter-platform agreement, particularly with LRT reagents, supporting their analytical reliability for laboratory assessment of DOAC exposure. Because exact dosing times were unavailable, these concentrations should be interpreted as heterogeneous spot samples rather than standardized pharmacokinetic reference intervals; these findings may nonetheless support individualized interpretation of outpatient spot sample DOAC concentrations in selected clinical settings."

Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular

A Survey on Anticoagulation Practices in Patients with Chronic Kidney Disease in Saudi Arabia. (PubMed, J Clin Med) - "While unfractionated heparin and warfarin remain central in patients with stage 5 CKD or on dialysis, DOAC use-particularly apixaban-has expanded, often with empiric dose reduction. These findings underscore the need for clearer guidance, standardized approaches to renal function assessment, multidisciplinary care pathways, and prospective studies focusing on anticoagulation use in CKD populations."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Nephrology • Renal Disease • Thrombosis • Venous Thromboembolism

New Perspectives on the Potential Mechanisms, Prevention and Treatment of Deep Vein Thrombosis Complicated by Lung Cancer (IASLC-WCLC 2026) - "Stratified anticoagulation efficacy : Stratified anticoagulation strategies show significant clinical effects for lung cancer-associated DVT: perioperative patients with CrCl ≥ 30 mL/min benefit from 7-10 days, with extended prophylaxis up to 4 weeks in high-risk patients, of LMWH prophylaxis; locally advanced/metastatic patients with low bleeding risk can be treated with DOACs (rivaroxaban/apixaban). Natural products such as Didang Decoction show promising adjuvant application value. Further research on molecular mechanisms and dynamic monitoring techniques is urgently needed to develop individualized antithrombotic regimens for lung cancer patients."

Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombosis • Venous Thromboembolism • CXCL8

Apixaban Use Before Kidney Transplantation: Is Reversal Necessary? (PubMed, Pharmacotherapy) - "Withholding preoperative 4F-PCC in apixaban-treated KTR appears safe, with surgical-bed bleeding rates comparable to those in patients who received preoperative 4F-PCC. Findings support individualized rather than routine preoperative reversal strategies to balance bleeding and thrombotic risks."

Journal • Retrospective data • Cardiovascular • Transplantation • Venous Thromboembolism

Apixaban Versus LMWH in CAT/VTE: A Comment on Clinical and Methodological Heterogeneity. (PubMed, Cardiovasc Drugs Ther) - "Observational before-after and quality-improvement studies are also vulnerable to secular trend bias, and acute treatment should not be merged with extended therapy. Future meta-analyses should use drug-specific stratification, time-standardized or hazard-based methods, concurrent controls, and phase-specific analyses to better estimate apixaban's effect while preserving clinically meaningful differences between indications and treatment phases in cancer-associated thrombosis across settings and improving decision-making in practice."

Heterogeneity • Journal • Cardiovascular • Hematological Disorders • Oncology • Thrombosis

Incidence and Predictors of Anticoagulant-Associated Bleeding in Patients With Venous Thromboembolism. (PubMed, J Clin Med Res) - "Low-molecular-weight heparin was the most commonly prescribed initial anticoagulant (39.0%), followed by warfarin (32.7%) and direct oral anticoagulants (25.1%), of which apixaban was the most frequently used (12.7%). Anticoagulant-associated bleeding is common among Thai patients with VTE and is associated with an increased risk of all-cause mortality. Patients with advanced age, poor performance status, low BMI, or concomitant antiplatelet therapy may benefit from closer monitoring during anticoagulant treatment."

Journal • Cardiovascular • Hematological Disorders • Oncology • Venous Thromboembolism

Extensive Iliofemoral Deep Vein Thrombosis Secondary to Uterine Leiomyoma-Induced Iliac Vein Compression: A Case Report. (PubMed, Cureus) - "The patient was managed with therapeutic anticoagulation, blood transfusion, and intravenous iron therapy, followed by definitive hysterectomy approximately two months later, with guideline-directed perioperative apixaban interruption and resumption without bridging anticoagulation. This case highlights the importance of cross-sectional imaging in identifying pelvic mass effect as an underrecognized cause of extensive unilateral DVT and the need for definitive treatment of the underlying compressive pathology."

Journal • Cardiovascular • Gynecology • Hematological Disorders • Pain • Solid Tumor • Thrombosis • Uterine Leiomyoma • Venous Thromboembolism

From Dyspnea to Suspected Breast Cancer: A Post-traumatic Hematoma as a Diagnostic Pitfall. (PubMed, Cureus) - "The patient reported a recent fall with subsequent ecchymosis of both breasts while on chronic anticoagulant therapy with apixaban...Histological confirmation was therefore required. Persistent clinical-radiological discordance required a multidisciplinary approach. The decision to repeat the assessment after an appropriate follow-up was essential to ensure diagnostic safety and avoid both delayed cancer diagnosis and unnecessary overtreatment."

Journal • Breast Cancer • Mood Disorders • Oncology • Pulmonary Disease • Solid Tumor

Resumption of Direct Oral Anticoagulants After Gastrointestinal Bleeding in Atrial Fibrillation: A Systematic Review of Timing and Clinical Outcomes. (PubMed, Cureus) - "Rivaroxaban carried the one clear excess rebleeding signal, favoring apixaban after prior GIB. Individualized risk assessment should guide decisions pending trial data."

Clinical data • Journal • Review • Atrial Fibrillation • Cardiovascular • Gastroenterology • Hematological Disorders • Renal Disease

Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Cardiol Rev) - "We included 3 RCTs, ODIn-AF (Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation), ALONE-AF (AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation), and OCEAN (Optimal Anticoagulation for Higher-Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial), enrolling patients at least 6 months postablation with no recurrent atrial arrhythmias...In patients remaining arrhythmia-free for at least 6 months after AF ablation, discontinuation of OAC was associated with fewer bleeding events without a statistically significant increase in thromboembolic risk. These hypothesis-generating findings highlight the need for larger, well-powered RCTs to better inform postablation anticoagulation strategies."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular